Laboratory of toxicology in vitro

Department of Biological Testing

Head: Elena Navolotskaya, D.Sc
navolotskaya@bibch.ru+7(4967)73-66-68#3205

peptides, receptors, signal transduction

The principal goal of the scientific activities of research workers of the laboratory is the study of properties and mechanism of action of biological active peptides. During the time of Laboratory existence new scientific results concerning structure and function of biological active peptides were obtained. The results also have a great practical importance: the peptides that combine a high specific activity with an almost complete absence of toxicity and immunogenicity are a valuable material for the development of new effective drugs.

The Laboratory collaborates with the Laboratory of Regulatory Proteins and the Laboratory of Biological Testing of the Institute’s Branch in Pushchino, the Laboratory of Hormonal Regulation Proteins of the IBCh, the Institute of Molecular Genetics RAS, the Blokhin Russian Cancer Research Center, the Research Institute of Pure Biochemicals (Saint Petersburg), the Institute of Cell Biophysics RAS, Joint Biotechnology Laboratory of University of Turku (Finland).

The Laboratory was established in 2005 on the basis of a Group of Regulatory Proteins of the Institute’s Branch in Pushchino.

  • Study of peptides properties and its action mechanism – fragments and analogues of natural peptide hormones.
  • Drug development that increasea the adaptive capacity of the body by the action of a variety extreme environmental factors.
  • We have established the main stages of the molecular mechanism of non-opioid action of beta-endorphin: binding to high affinity and specificity receptor of target cell → increase in activity of inducible NO-synthase (iNOS) → increase in the NO production → increase in the soluble guanylate cyclase (sGC) activity → increase in intracellular levels of cyclic guanosine-3’,5′ monophosphate (cGMP).
  • We synthesized a peptide octarphin (TPLVTLFK) and its cyclic analog cyclo(TPLVTLFK), capable when administered to rats subjected to the action of various extreme factors (temperature shock, hypoxia, ischemia, myocardial infarction) improve coronary blood flow, improve the contractile activity of the myocardium, reduce the intensity of lipid oxidation, increase the level of antioxidant protection. Both peptides are potentially useful for the development of drugs increasing resistance of the heart muscle to the stress and may find use as cardioprotectors and for preventing and therapy of coronary heart disease and myocardial infarction.
NamePositionContacts
Elena Navolotskaya, D.Scheadnavolotskaya@bibch.ru+7(4967)73-66-68#3205
Vladimir Sadavnikov, Ph.D.s. r. f.svb@bibch.ru
Julija NekrasovaPhD stud.nekr-jul@mail.ru

All publications (show selected)

Loading...

Elena Navolotskaya

  • Russia, Moscow, Ul. Miklukho-Maklaya 16/10 — On the map
  • IBCh RAS, build. ФИБХ, office. Лаб-1/402
  • Phone: +7(4967)73-66-68#3205
  • E-mail: navolotskaya@bibch.ru

Mechanism of the nonopioid β-endorphin action on the activity of the hypothalamic–pituitary–adrenal axis

In collaboration with Laboratory of hormonal regulation proteins

The binding of β-endorphin to a nonopioid receptor on the anterior pituitary cells has been found to increase the expression of inducible NO-synthase, which leads to a decrease in the secretion of ACTH and corticosterone. Thus, it has been shown that the nonopioid β-endorphin receptor and its agonists are involved in the regulation of the activity of the hypothalamic–pituitary–adrenal axis at the level of the pituitary and adrenal glands.

Molecular mechanism of the non-opioid beta-endorphin action

In collaboration with Laboratory of hormonal regulation proteins,  Laboratory of pharmacokinetics

Using a synthetic peptide octarphin (TPLVTLFK), a selective agonist of non-opioid beta-endorphin receptor, data on the molecular mechanism of the non-opioid action of the hormone have been obtained. It was found that the non-opioid effect of beta- endorphin on the target cell is realized by the following way: increase in the inducible NO synthase expression → increase in NO production → increase in the activity of soluble guanylate cyclase → increase in the intracellular level of cGMP.